← All trials
NCT02004769
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- Jun 1, 2016
- Completion date
- Jun 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 67
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Fudan UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- Southern Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Shandong Tumor HospitalCollaborator
- Zhejiang UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Soochow UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.